26 Week Open Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed).
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 17 Jan 2013
At a glance
- Drugs Ziprasidone (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 22 Jun 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 21 May 2010 New trial record